Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects

Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects

(2014) Dongyang Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

pH-Dependent Drug–Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development

(2014) L Zhang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Vemurafenib oral bioavailability: An insoluble problem

(2014) Russell Z. Szmulewitz et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

(2013) Gillian S. Smelick et al.   MOLECULAR PHARMACEUTICS

Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer

(2012) Madhavi Nagilla et al.   ADVANCES IN THERAPY

Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers

(2012) Ophelia Q. P. Yin et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

(2012) Yazdi K. Pithavala et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Virtue of Low-Flow Toilets

(2012) Michael N. Needle   JOURNAL OF CLINICAL ONCOLOGY

Fast and Flawed or Scientifically Sound: The Argument for Administering Oral Oncology Drugs During Fasting

(2012) Mary Todd et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects

(2011) Paul Martin et al.   CLINICAL THERAPEUTICS

Flushing Oral Oncology Drugs Down the Toilet

(2011) Mark J. Ratain   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Food and Oral Antineoplastics: More Than Meets the Eye

(2010) R. K. Jain et al.   CLINICAL CANCER RESEARCH

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products

(2010) S. P. Kang et al.   CLINICAL CANCER RESEARCH

A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors

(2010) E I Heath et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib

(2010) Ophelia Q. P. Yin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population-Based Mechanistic Prediction of Oral Drug Absorption

(2009) Masoud Jamei et al.   AAPS Journal

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

(2009) Jie Ling et al.   ANTI-CANCER DRUGS

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

(2009) Merrill J. Egorin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

(2009) C Tanaka et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects

(2009) Timothy Eley et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Current Methods for Predicting Human Food Effect

(2008) Kimberley A. Lentz   AAPS Journal